Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENABLE: venetoclax plus decitabine for secondary AML arising from myeloproliferative neoplasms
2023-510241-16-00Phase 2Authorised
- Sponsor
- GIMEMA
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and decitabine in acute myeloid leukemia (AML), sponsored by GIMEMA. Primary endpoint: Event-free survival at 1 year. Planned start Dec 2021; status: authorised.
02
Drugs
venetoclaxdecitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2023-510241-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510241-16-00.